The FinnGen project is based on exceptionally wide and open co-operation. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, biobanks, international pharmaceutical companies and hopefully hundreds of thousands of Finns.
A graph where citizens are at the center, surrounded by FinnGen partners and stakeholders: pharma companies, hospital districts, hospitals, universities, biobanks, healthcare industry and Business Finland.
Project partners

The FinnGen research project involves all the same actors as drug development: universities, hospitals, biobanks and pharmaceutical companies. With this open cooperation, we hope to speed up the emergence of new innovations.

Coordinating organizations:

University of Helsinki (Institute for Molecular Medicine Finland, FIMM) is coordinating the FinnGen study. Helsinki Biobank (the Hospital District of Helsinki and Uusimaa) coordinates the sample collection and THL acts as the data controller of the register data.

Logos of the coordinating organizations: University of Helsinki/FIMM, HUS/Helsinki Biobank, THL/THL Biobank










Funded by:


Business Finland


and the funding research partners:

AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Squibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.

Logos of the companies funding the study (listed above).


In cooperation with the Finnish Biobank cooperative FINBB and these Finnish biobanks:

  • Auria Biobank
  • Helsinki Biobank
  • Hematological Biobank (FHRB Biobank)
  • Biobank of Eastern Finland
  • Central Finland Biobank
  • Northern Finland Biobank Borealis
  • Finnish Clinical Biobank Tampere
  • THL Biobank
  • Blood Service Biobank


Logos of the Finnish biobanks participating in FinnGen, and a list of the host organisations of each biobank. This information can be found by following the link below the image.

The host organisations of the above listed biobanks are described here.